Merus to Present at the Cowen & Co. 37th Annual Health Care Conference
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
Chief Executive Officer, will present a company overview at the Cowen & Co.
37(th) Annual Health Care Conference on Monday, March 6, 2017 at 4:00 p.m. ET at
the Boston Marriott Copley Place.
A live webcast of the presentation will be available on the Investors page of
the Company's website, http://www.merus.nl. An archived presentation will be
available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe
as a potential treatment for HER2-expressing solid tumors. Merus' second
bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2
clinical trial in patients with acute myeloid leukemia. The Company also has a
pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem cells
and is being developed as a potential treatment for colorectal cancer and other
solid tumors, and Biclonics® designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.02.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 526804
Anzahl Zeichen: 2564
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus to Present at the Cowen & Co. 37th Annual Health Care Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
